{
  "docId": "019de076-2351-76a2-9dc5-1c75bf1dd158",
  "docSlug": "905d9ceaf5cb608feb86b583a8401e54",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 45,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "thesis_headline",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a navigation bar at the top indicating the current section is 'BioPharmaceuticals'.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2351-76a2-9dc5-1c75bf1dd158/26",
  "deckHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158",
  "deckJsonHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158.json",
  "deckAnchorHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Strong track record in cardio renal metabolic diseases, opportunity for monotherapy and combinations to address broad range of co-morbid diseases",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "171cf66c-1325-4cfe-bc55-85498e1277be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.58,
        "x": 0.38,
        "y": 0.32
      },
      "kind": "chart",
      "text": "1bn people living with obesity; Obesity is driver for >200 chronic diseases",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "882062c0-acfa-4082-8b39-fe94736afba1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.58,
        "x": 0.38,
        "y": 0.58
      },
      "kind": "diagram",
      "text": "Farxiga (on-market), AZD6234 (Phase I), baxdrostat (Phase III), mitiperstat (Phase II), AZD5462 (Phase I), AZD0780 (Phase I)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94fc1f04-9a92-41eb-97b3-ca37dd2b833f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.06,
        "y": 0.38
      },
      "kind": "list",
      "text": "Potential for no titration; High bioavailability, favourable tolerability profile; Novel once-daily oral small molecule; Efficacy at low doses – 10 to 30mg",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4767f7ca-4b66-4ffc-aa08-d778f4594d7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.28,
        "x": 0.06,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "ECC5004 (GLP-1RA) global development and commercialisation rights",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00f23d88-71f9-4abc-bddd-8a6b12486dee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Accelerating presence in obesity with ECC5004, a novel once-daily oral GLP-1RA",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fa9cced-1332-4f13-81a2-b88da77608a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6314c37-6b53-4c55-aad7-bd7fe62ce958",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "17b92734-7d41-44a8-9595-62ce885fe80f",
      "evidence": "diagram/process: Farxiga (on-market), AZD6234 (Phase I), baxdrostat (Phase III), mitiperstat (Phase II), AZD5462 (Phase I), AZD0780 (Phase I)",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}